Be the first to know

Never miss an update from Mesoblast. Did you know that during reporting season, the announcements from ASX:MSB often move the market?

Mesoblast (ASX:MSB) Company Logo

By joining StockLight, you agree to our Terms & Conditions and Privacy Policy

Mesoblast (MSB)

AU ASX:MSB (2.2B)

3.85
+0.07 (1.85%)
4pm Monday Aug 03 AEST
LOADING
Loading price chart..

Summary

Current Price: $3.85
52w High/Low: $1.02 - 4.45
Market Cap: 2.2B
Price/Earnings: -
Dividend Yield: -
Volume/Average: 7.1M - 2.3M
Mesoblast (ASX:MSB) Company Logo

Listed in 2004

A biotechnology company in the area of adult stem cell technology.
Mesoblast (ASX:MSB) Company Logo

A biotechnology company in the area of adult stem cell technology.

Annual Reports

Annual Report to shareholders Oct 29th 2019
2019
(5.4mb)
Annual Report to shareholders Oct 30th 2018
2018
(2.5mb)
Annual Report to shareholders Oct 16th 2017
2017
(3.0mb)
Annual Report to shareholders Oct 21st 2016
2016
(6.3mb)
Preliminary Final Report (Including Appendix 4E) Aug 24th 2016
2016
(5.9mb)
Annual Report to shareholders Sep 21st 2015
2015
(3.9mb)

Dividend History

No dividends found.

Quantitative Ratios

Stock Ratios Locked
You viewed 3 companies today
Ratios will be unlocked
again tomorrow or;

Unlock these ratios,
configure alerts
and much more...

Download StockLight

All Ratios, Alerts and other features are available in our iOS and Android apps:
Download on iOS Download on Android

We are working on updating this web app to fully enable Quantitative Ratios. All other current web features including annual reports, price sensitive announcements, dividends and earnings transcripts are free to use here on our web app.
Dividend Yield
0.6%
 
0.0%
 
 
Industry Avg
MSB

UNATTRACTIVE: Mesoblast's dividend yield of 0.0% is less than the industry average for pharmaceuticals, biotechnology & life sciences stocks listed on the ASX. more
Implied Growth
35.9%
 
13.4%
 
 
Industry Avg
MSB

ATTRACTIVE: Mesoblast exhibits an implied growth ratio which is less than the industry average for pharmaceuticals, biotechnology & life sciences stocks listed on the ASX. MSB calculation: 10% - (-$0.13 / $3.85) = 13.4% more
Price / Book
5.1
 
3.3
 
 
Industry Avg
MSB

ATTRACTIVE: Mesoblast exhibits a price/book ratio which is less than the industry average for pharmaceuticals, biotechnology & life sciences stocks listed on the ASX. more
Price / Sales
15.2
 
43.5
 
 
Industry Avg
MSB

UNATTRACTIVE: Mesoblast exhibits a price/sales ratio which exceeds the industry average for pharmaceuticals, biotechnology & life sciences stocks listed on the ASX. more

Company News

Here's how to start investing with $5k
August 1st, 2020 - Motley Fool

Like many things in life, the hardest part of investing can be getting started! Here's how to begin the journey to building your ASX share portfolio. The post Here's how to start investing with $5k appeared first on Motley Fool Australia.

Why this broker thinks Mesoblast shares are a strong buy
July 31st, 2020 - Motley Fool

The Mesoblast limited (ASX:MSB) share price could be heading higher from here according to one Australian broker... The post Why this broker thinks Mesoblast shares are a strong buy appeared first on Motley Fool Australia.

Mesoblast share price pushes higher ahead of the “most significant period in its history”
July 30th, 2020 - Motley Fool

The Mesoblast limited (ASX:MSB) share price is pushing higher on Thursday ahead of the "most significant period in its history" The post Mesoblast share price pushes higher ahead of the “most significant period in its history” appeared first on Motley Fool Australia.

3 junior ASX healthcare shares with explosive growth potential
July 27th, 2020 - Motley Fool

For investors wishing to diversity into the healthcare sector, but who also want to look beyond big names like Cochlear Limited and CSL Limited, here are 3 junior ASX healthcare shares with long growth runways ahead of them. The post 3 junior ASX healthcare shares with explosive growth potential appeared first on Motley Fool Australia.

ASX 200 drops 1.1%: Big four banks fall, Resolute rockets, Afterpay tumbles
July 22nd, 2020 - Motley Fool

Afterpay Ltd (ASX:APT) and Resolute Mining Limited (ASX:RSG) shares are making waves on the ASX 200 on Wednesday. Here's why... The post ASX 200 drops 1.1%: Big four banks fall, Resolute rockets, Afterpay tumbles appeared first on Motley Fool Australia.

Why Afterpay, BHP, Cann, & Mesoblast shares are tumbling lower
July 22nd, 2020 - Motley Fool

Afterpay Ltd (ASX:APT) and BHP Group Ltd (ASX:BHP) shares are two of four tumbling notably lower on the ASX on Wednesday. Here's why... The post Why Afterpay, BHP, Cann, & Mesoblast shares are tumbling lower appeared first on Motley Fool Australia.

Why Mesoblast might be the best ASX healthcare growth share to own right now
July 21st, 2020 - Motley Fool

The Mesoblast share price has skyrocketed 260% since March. Here we look at the key drivers behind the gains and whether Mesoblast is a buy. The post Why Mesoblast might be the best ASX healthcare growth share to own right now appeared first on Motley Fool Australia.

4 exciting ASX biotech shares surging higher today
July 21st, 2020 - Motley Fool

The ASX biotech segment has been on fire today. Here we take a closer look at 4 ASX biotech shares that have seen particularly strong share price gains today. The post 4 exciting ASX biotech shares surging higher today appeared first on Motley Fool Australia.